FDGmean uptake at day 1 relative to baseline showed a significant reduction in tumor FDGmean uptake in the Pan-HER treated mice compared with the mice treated with vehicle (p ≤ 0.001) or anti-HER2 (p ≤ 0.01) (Figure 2F). The gene discussed is ERBB2; the disease is neoplasm.